Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | LTK | P29376 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.50 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6917745 | 0.86 | IDO1 (0.41) | CSF1RMAP4K4FGFR1PDGFRALTK | |
| SCHEMBL6919278 | 0.84 | ENPP1 (0.43) | CDK4CCND1ENPP1HPGDALOX15 | |
| SCHEMBL6820273 | 0.82 | KDR (0.67) | CSF1RMAP4K4FGFR1PDGFRALTK | |
| SCHEMBL6920865 | 0.82 | SERPINE1 (0.41) | ALDH1A1GAAMAPTLMNASMN1; SMN2 | |
| SCHEMBL6661870 | 0.76 | NISCH (0.33) | FGFR1KDRCYP3A4ALDH1A1ALOX15 | |
| SCHEMBL30896407 | 0.76 | GPR3 (0.45) | CSF1RMAP4K4FGFR1PDGFRALTK | |
| SCHEMBL6915290 | 0.74 | JAK2 (0.41) | FGFR1KDRDYRK1BCDK4CCND1 | |
| SCHEMBL6913853 | 0.70 | NMT2 (0.43) | KDRCLK4CDK4CCND1FEN1 | |
| SCHEMBL6919545 | 0.70 | NMT2 (0.49) | MAP4K4KDRCLK4CYP3A4CYP2C9 | |
| SCHEMBL31690911 | 0.67 | KDR (1.00) | CSF1RMAP4K4FGFR1PDGFRALTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340412-A1 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | IOVANCE BIOTHERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230340412-A1 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | IOVANCE BIOTHERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230165898-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEROF | IOVANCE BIOTHERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20220133795-A1 | Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof | IOVANCE BIOTHERAPEUTICS, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20220118011-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20200347350-A1 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | IOVANCE BIOTHERAPEUTICS INC (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200224161-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS, INC. | 2020-07-16 | — | — | US | disclosed |
| WO-2004016270-A1 | USE OF Itk INHIBITORS FOR THE TREATMENT OF MAST CELL-DRIVEN OR BASOPHIL-DRIVEN DISEASES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004016615-A1 | PYRAZOLO (4,3c) CINNOLINE COMPOUNDS AS INHIBITORS OF ITK KINASE ACTIVITY | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200224161-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | PBK, MALT1, BCL9L | CSF1R 160/4885MAP4K4 3585/4885FGFR1 841/4885 |
| US-20230340412-A1 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | LTK, LIFR, PBK | CSF1R 96/4885MAP4K4 3512/4885FGFR1 366/4885 |
| US-20230165898-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEROF | CD47, LTK, PBK | CSF1R 150/4885MAP4K4 4621/4885FGFR1 305/4885 |
| US-20220133795-A1 | Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof | PBK, LTK, CD47 | CSF1R 166/4885MAP4K4 3998/4885FGFR1 471/4885 |
| US-20200347350-A1 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | LTK, LIFR, PBK | CSF1R 96/4885MAP4K4 3512/4885FGFR1 366/4885 |
| US-20220118011-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | ICOS, PBK, IL2 | CSF1R 387/4885MAP4K4 3515/4885FGFR1 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.